stockrow
Friday 6 November 2026
Export BMRA’s income statement to Excel — free account
Biomerica, Inc.
BMRA Healthcare Medical Devices
Biomerica, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $4.5 million, down 16.2% from fiscal 2025.
- Revenue
- −8.33%
- EPS
- −46,350.0%
- Free cash flow
- −199.3%
Quarter to August 2026, against a year earlier
1.61
0.00
0.00%
Follow BMRA
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to May
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM Aug ’26 | Trend | 10 yrs | 2027e | 2028e | 2029e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | 6 | 6 | 5 | 7 | 7 | 19 | 5 | 5 | 5 | 4 | 4 | (2.9%) | — | — | — | — | |
| Gross margin, % | 34.91 | 31.53 | 24.84 | 25.97 | 5.09 | 15.78 | 8.35 | 11.28 | 9.38 | 8.13 | 0.95 | (26.8) pt | ||||||
| EBT | (1) | (1) | (2) | (3) | (7) | (5) | (7) | (6) | (5) | (4) | (5) | +17.1% | ||||||
| EBT margin, % | (15.69) | (25.77) | (45.55) | (39.89) | (103.25) | (23.88) | (132.78) | (109.62) | (93.62) | (84.26) | (114.87) | (68.6) pt | ||||||
| Net income | (1) | (1) | (2) | (3) | (7) | (5) | (7) | (6) | (5) | (4) | (5) | +17.1% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 5.56 | 5.19 | 4.52 | 5.27 | 4.83 | 11.91 | 3.02 | 2.57 | 2.31 | 1.53 | 1.32 | (13.4%) | |||||
| Earnings | (0.88) | (1.36) | (2.08) | (2.11) | (4.99) | (2.88) | (4.00) | (2.88) | (2.16) | (1.30) | (1.64) | +4.4% | ||||||
| Cash flow | (0.69) | (1.10) | (1.95) | (3.38) | (3.52) | (0.30) | (3.09) | (2.55) | (1.67) | (1.17) | (1.20) | +6.0% | ||||||
| Capex | (0.09) | (0.12) | (0.15) | (0.09) | (0.20) | (0.11) | (0.04) | (0.05) | (0.02) | 0.00 | 0.00 | (47.1%) | ||||||
| Free cash flow | (0.79) | (1.22) | (2.10) | (3.48) | (3.72) | (0.41) | (3.14) | (2.60) | (1.69) | (1.17) | (1.20) | +4.5% | ||||||
| Book value | 4.31 | 4.04 | 3.46 | 11.18 | 6.19 | 5.26 | 6.63 | 3.13 | 1.79 | 0.90 | 1.11 | (16.0%) | ||||||
| Shares, m | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | +12.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | 3.60 | 6.27 | 3.99 | 9.65 | 6.05 | 2.35 | 3.63 | 1.80 | 1.47 | 1.54 | 1.22 | 4.0 | ||||||
| P/B | 4.64 | 8.06 | 5.21 | 4.55 | 4.72 | 5.33 | 1.65 | 1.48 | 1.90 | 2.62 | 1.45 | 4.0 | ||||||
| EV/Sales | 3.38 | 6.05 | 3.85 | 8.35 | 5.46 | 2.04 | 1.81 | 1.03 | 1.01 | 1.25 | 0.59 | 3.4 | ||||||
| EV/FCF | (23.21) | (25.74) | (8.30) | (12.66) | (7.09) | (59.23) | (1.73) | (1.02) | (1.37) | (1.60) | (0.64) | (14.2) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (1) | (1) | (2) | (4) | (5) | 0 | (5) | (5) | (4) | (3) | (4) | +18.9% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (39.8%) | ||||||
| Free cash flow | (1) | (1) | (2) | (4) | (6) | (1) | (6) | (5) | (4) | (3) | (4) | +17.2% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 4 | 4 | 3 | 13 | 8 | 7 | 11 | 6 | 3 | 2 | 3 | (9.3%) | |||||
| Net debt | (1) | (1) | (1) | (9) | (4) | (6) | (10) | (4) | (2) | (1) | (3) | +0.7% | ||||||
| Shareholders’ equity | 4 | 4 | 4 | 14 | 9 | 8 | 12 | 7 | 4 | 3 | 4 | (5.8%) | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (16.91) | (28.63) | (45.72) | (23.79) | (51.21) | (39.07) | (55.29) | (50.43) | (65.44) | (59.43) | (67.12) | (42.5) pt | |||||
| ROIC | (18.28) | (29.67) | (45.78) | (30.74) | (93.23) | (117.68) | (225.16) | (164.37) | (188.20) | (251.51) | (370.83) | (233.2) pt | ||||||
| ROE | (18.72) | (33.26) | (57.62) | (29.47) | (63.60) | (51.63) | (71.23) | (65.28) | (92.99) | (112.10) | (113.80) | (93.4) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 39 | 39 | 39 | 45 | 49 | 64 | 62 | 64 | 54 | 50 | — | +2.8% | |||||
| Revenue/emp, $m | 0.15 | 0.14 | 0.13 | 0.15 | 0.15 | 0.29 | 0.09 | 0.08 | 0.10 | 0.09 | — | (5.5%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to May 2026 · latest quarter Aug 2026 · fundamentals updated 2 Nov 2026
Biomerica, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| BTCY Biotricity Inc. | $10.9M | — (loss-making) | — (loss-making) | +10.40% (above 0%: growing) | n/m | +235.83% (above 0%: growing) | 82.55% | 3.70% | Compare |
| AEMD Aethlon Medical, Inc. | $8.5M | — (loss-making) | — (loss-making) | +335.00% (above 0%: growing) | n/m | −11.13% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| NMTC NeuroOne Medical Technologies Corporation | $7.8M | — (loss-making) | — (loss-making) | +16.33% (above 0%: growing) | n/m | +26.91% (above 0%: growing) | 59.94% | (122.87%) | Compare |
| BMRA Biomerica, Inc. | $7.4M | — (loss-making) | 11.4× | −8.33% (below 0%: shrinking) | n/m | −199.25% (below 0%: shrinking) | 8.14% | (97.00%) | |
| INBS Intelligent Bio Solutions Inc. | $5.8M | — (loss-making) | — (loss-making) | +51.10% (above 0%: growing) | n/m | −31.59% (below 0%: shrinking) | 43.23% | (360.19%) | Compare |
| TBIO Telesis Bio Inc. | $5.3M | — (loss-making) | — (loss-making) | −71.85% (below 0%: shrinking) | n/m | −17.96% (below 0%: shrinking) | 64.43% | (349.74%) | Compare |
| VNRX VolitionRX Limited | $5.3M | — (loss-making) | — (loss-making) | −1.97% (below 0%: shrinking) | n/m | +18.58% (above 0%: growing) | 100.00% | (1,042.39%) | Compare |
| BDMD Baird Medical Investment Holdings Limited | $5.0M | — (loss-making) | — | — | n/m | −598.12% (below 0%: shrinking) | — | — | Compare |
| NVNO enVVeno Medical Corporation | $4.8M | — (loss-making) | — (loss-making) | +0.32% (above 0%: growing) | n/m | +27.64% (above 0%: growing) | 0.00% | 0.00% | Compare |
| Median of peers | $5.6M | — | — | +10.40% | — | +3.73% | 59.94% | (122.87%) |
Pay and ownership Proxy statement filed 16 October 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2026 | 285.45k | 241.21k | 21.81 |
| 2025 | 201.03k | 177.70k | 27.83 |
| 2024 | 360.10k | 199.84k | 42.38 |
Ownership
Directors and executive officers, together
12.30%
B. Riley Principal Capital, LLC
10.00%
Zackary S. Irani
7.10%
Zackary Irani
7.10%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement